CALR and essential thrombocythemia: Both are multicenter, open-label, first-in-human studies with a phase 1a dose-escalation stage in high-risk MF or ET patients harboring exon 9 CALR mutations, followed by phase 1b expansion and phase 1c crossover with ruxolitinib in MF patients with suboptimal response.